News
New prescriptions of Esyma are suspended by MHRA
In December, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - three resulting in a liver transplant - were...
News
Richard Wolf Announces the Opening of New Office in Singapore
Richard Wolf, answering strong global demand for its high-performance endoscopic technology services, today announced plans to expand in Southeast Asia by opening its 15th subsidiary to be located at the heart of Southeast Asia – Singapore. ...
News
Larotrectinib data published in The New England Journal of Medicine: Bayer
Bayer and Loxo Oncology, Inc., , a biopharmaceutical company from Stamford announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for the treatment of pediatric and adult patients whose tumors harbor Neurotrophic Tyrosine Receptor...
News
Envigo appoints Lynn Lewis as Senior Vice President of Global Sales
Envigo, a leading provider of nonclinical contract research services and research models, announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales. She brings extensive knowledge in both science and business...
News
Bristol-Myers Squibb and Nektar Therapeutics to collaborate for Nektar’s CD122-biased Agonist, NKTR-214
Bristol-Myers Squibb Company announced the companies have executed a global strategic development and commercialization collaboration for Nektar’s lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers...
News
Saneca Pharma appoints new CEO
Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král. Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked...
News
AbbVie raises dividend and buys $10 billion of shares
AbbVie Inc (ABBV.N) said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes. The Chicago-based...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read